The Blog

Vivodyne has raised $40 million in new Series A financing to scale its robotics+AI approach to testing on thousands of lab-grown, fully-functional human tissues, and the massive amount of human data they generate. With the new financing, Vivodyne will open a 23,000-square-foot fully robotic laboratory at Genesis Marina in South San Francisco.

Vivodyne, a San Francisco-based startup using lab-grown human tissues to discover and develop drugs, raised $40 million in a Series A led by Khosla Ventures.

Vivodyne is the latest startup from UPenn Bioengineering to raise $4 million in Seed Funding, led by Kairos Ventures

Vivodyne has been named #1 in the list of Fast Company’s World’s Most Innovative “Small but Mighty” Companies for 2022.

Our Co-Founder, Andrei Georgescu, recently took the stage at the Forbes Healthcare Summit to discuss how AI and human organ models are accelerating the future of drug discovery.

Julie will oversee business operations, strategic planning, finance, people operations, and multisite expansion, driving the company's operational excellence and strategic growth initiatives.

Vivodyne announces the appointment of Elliot Menschik, M.D., Ph.D., to the company’s Board of Directors and to the executive role of Chief Technology Officer (CTO).

Vivodyne announces the expansion of its leadership team with Dr. Ivana Mikic joining as its Vice President of Artificial Intelligence.

Vivodyne announces the expansion of its executive team with Dr. Susan Billings joining as its Chief Commercial Officer.

Vivodyne announces that it has expanded its leadership team with Anthony Bahinski, Ph.D., MBA, FAHA joining as its Chief Biotechnology Officer.

Vivodyne announces the close of $38 million in total seed financing, led by Khosla Ventures, with participation from Kairos Ventures, CS Ventures, MBX Capital, and Bison Ventures.

In this insightful conversation, our CEO delves into how Vivodyne enables human testing before clinical trials. Our innovative platform has the capacity to cultivate tens of thousands of human tissue models at scale, setting a new standard in the field.

Andrei Georgescu of Vivodyne discusses key advantages of its humanized drug testing platform and the impact of the FDA’s policy shift with Endpoints News.

In a roadmap to change animal testing requirements for INDs, the U.S. FDA said its new approach will improve drug safety, hasten the evaluation process, and lower costs for companies and patients. It’s another step in a process of changing rules put in place decades ago.

Firstword Pharma speaks with CEO & Co-Founder Andrei Georgescu about the recent FDA initiative aimed at eliminating the need to test monoclonal antibody therapeutics in animal models. Instead, the agency suggested that animal testing could be replaced with AI modelling or lab-grown human organoids.

Vivodyne could capitalize on the desire for new approaches to preclinical research.

Andrei Georgescu of Vivodyne discusses key advantages of its humanized drug testing platform and the impact of the FDA’s policy shift with Contract Pharma.